<code id='3811980042'></code><style id='3811980042'></style>
    • <acronym id='3811980042'></acronym>
      <center id='3811980042'><center id='3811980042'><tfoot id='3811980042'></tfoot></center><abbr id='3811980042'><dir id='3811980042'><tfoot id='3811980042'></tfoot><noframes id='3811980042'>

    • <optgroup id='3811980042'><strike id='3811980042'><sup id='3811980042'></sup></strike><code id='3811980042'></code></optgroup>
        1. <b id='3811980042'><label id='3811980042'><select id='3811980042'><dt id='3811980042'><span id='3811980042'></span></dt></select></label></b><u id='3811980042'></u>
          <i id='3811980042'><strike id='3811980042'><tt id='3811980042'><pre id='3811980042'></pre></tt></strike></i>

          fashion

          fashion

          author:Wikipedia    Page View:7536
          Tome cofounders Jonathan Gootenberg, left, and Omar Abudayyeh, a scientific team that's trying to reinvent gene editing for a new era of biotech innovation.
          Suzanne Kreiter/Globe staff

          WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads shot each other emails about how to solve a bioengineering equation. It has continued for 14 years over sushi dinners, between Marvel movies, and during rowing-machine workouts.

          Together, Omar Abudayyeh, 33, and Jonathan Gootenberg, 32, have probed the mysteries of genomic editing and COVID detection. They co-published 10 scientific papers, helped launch two medical-diagnostic companies, and cofounded a Watertown startup, Tome Biosciences, that reengineers genes and cells to cure diseases. They also run the Abudayyeh-Gootenberg Lab at Harvard.

          advertisement

          Gootenberg and Abudayyeh are an unusual pair, two scientists — a Jewish American and a Palestinian American — who prefer working together in a field that often draws solitary researchers and rewards individual achievement.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Walensky prepares to leave CDC — and Congress — behind
          Walensky prepares to leave CDC — and Congress — behind

          OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

          read more
          Kenai launches with $82 million for Parkinson’s stem cell therapy
          Kenai launches with $82 million for Parkinson’s stem cell therapy

          AdobeThedreamofbeingabletopluckacelltherapyoffofafreezershelfandspeedilygiveittocancerpatientsismate

          read more
          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more

          Readout Newsletter: Ironwood, Pfizer, FogPharma updates

          DavidLRyan/TheBostonGlobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourb